Schrödinger, Inc. (SDGR)
NASDAQ: SDGR · Real-Time Price · USD
24.17
+0.26 (1.09%)
At close: May 12, 2025, 4:00 PM
24.17
0.00 (0.00%)
After-hours: May 12, 2025, 5:38 PM EDT
Company Description
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications.
The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries.
The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations.
It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates.
Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Schrödinger, Inc.
| Country | United States |
| Founded | 1990 |
| IPO Date | Feb 6, 2020 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 891 |
| CEO | Ramy Farid |
Contact Details
Address: 1540 Broadway, 24th Floor New York, New York 10036 United States | |
| Phone | 212 295 5800 |
| Website | schrodinger.com |
Stock Details
| Ticker Symbol | SDGR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001490978 |
| CUSIP Number | 80810D103 |
| ISIN Number | US80810D1037 |
| Employer ID | 95-4284541 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ramy Farid Ph.D. | Chief Executive Officer, President and Director |
| Dr. Richard A. Friesner Ph.D. | Co-Founder, Scientific Advisory Chairman and Director |
| Dr. Geoffrey Craig Porges MBBS | Executive Vice President and Chief Financial Officer |
| Kenneth Patrick Lorton | Executive Vice President, Chief Technology Officer and Chief Operating Officer of Software |
| Dr. Robert Lorne Abel Ph.D. | Executive Vice President, Chief Scientific Officer of Platform and Head of Modeling Research & Development |
| Dr. Karen Akinsanya Ph.D. | President of Research and Development Therapeutics |
| Prof. William Goddard III | Co-Founder and Scientific Advisor |
| Shane Brauner | Executive Vice President and Chief Information Officer |
| Jaren Irene Madden | Senior Vice President of Investor Relations and Corporate Affairs |
| Yvonne Tran Esq. | Corporate Secretary, Chief Legal and People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 7, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 7, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 8-K | Current Report |
| Apr 24, 2025 | ARS | Filing |
| Apr 24, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 14, 2025 | 144 | Filing |
| Apr 11, 2025 | 8-K | Current Report |
| Mar 10, 2025 | 8-K | Current Report |
| Mar 6, 2025 | 144 | Filing |